First patent granted in Japan for Iconovo’s ICOone

Iconovo AB (publ), that develops complete inhalation products for a global market, today announces that the Japanese patent authority JPO has submitted a Notice of Allowance regarding Iconovo's patent application for the inhaler platform ICOone. The patent describes the single-dose inhaler which is currently part of three innovative partner projects including the administration of oxytocin and covid-19 vaccine. Iconovo already has a well-established patent portfolio for ICOone in Sweden, Europe (EPO), USA, China, and India.

Iconovo updates its long-term financial targets – expects strong revenue growth with a high margin

Iconovo AB (publ), that develops complete inhalation products for a global market, today announces its five-year targets for the company. The company expects to reach sales of SEK 250 million in 2027. The target for the operating profit in the same year is SEK 125 million, resulting in an operating margin of 50 percent. The company expects about one third of the revenue stream to come from Iconovo's own pharmaceutical sales in the Nordic region through its subsidiary Iconovo Pharma. Iconovo's future prospects and financial targets was described in more detail at a Capital Markets Day in Swedish and the presentations will soon be available on the company´s website.

Iconovo uppdaterar sina långsiktiga finansiella mål – ser stark intäktsökning med hög marginal

Iconovo AB (publ), som utvecklar kompletta inhalationsprodukter för en global marknad, tillkännager idag sina femårsmål för verksamheten. År 2027 räknar bolaget med att uppnå en försäljning om 250 miljoner kronor. Målet för rörelseresultatet samma år är 125 miljoner kronor, motsvarande en rörelsemarginal på 50 procent. Cirka en tredjedel av omsättningen beräknas komma från Iconovos egen läkemedelsförsäljning i Norden genom dotterbolaget Iconovo Pharma. Iconovos framtidsutsikter och finansiella mål kommer att beskrivas mer utförligt vid en kapitalmarknadsdag senare idag, se information nedan.

Iconovos samarbetspartner ISR tecknar avtal med Gerresheimer för storskalig produktion av ICOone Nasal

Iconovo AB (publ) meddelar att samarbetspartnern Immune System Regulation AB (ISR) tecknat avtal med Gerresheimer för storskalig produktion av ICOone näsinhalatorer inför ISR:s kliniska fas III-studie. Tillverkningsavtalet är ett styrkebesked för ICOone som visar att tekniken är väl anpassad för storskalig produktion tack vare sin låga tillverkningskostnad och lättarbetade design. Iconovo samverkar med bolagen i den pågående tekniköverföringen.

Abbreviated interim report 1 January – 31 March 2022

Significant successes for ICOres and ICOone

Iconovo and Galenica enters a strategic collaboration for the development of new inhalation products

Iconovo AB (publ), that develops complete inhalation products for a global market, has entered into a strategic collaboration with Galenica AB – a company specializing in the development and manufacture of pharmaceuticals for clinical studies. The main purpose of the collaboration is to facilitate the manufacturing of clinical trial material for companies developing new drugs for Iconovo's innovative single dose inhaler ICOone.

Iconovo inleder ett strategiskt samarbete med Galenica för utveckling av nya inhalationsläkemedel

Iconovo AB (publ), som utvecklar kompletta inhalationsprodukter för en global marknad, har inlett ett strategiskt samarbete med Galenica AB – ett företag specialiserat på utveckling och tillverkning av läkemedel för kliniska studier. Samarbetet syftar främst till att underlätta produktionen av kliniskt prövningsmaterial för bolag som utvecklar nya läkemedel med hjälp av Iconovos innovativa engångsinhalator ICOone.

Iconovo extends collaboration with ISR with an agreement worth 13.6 million Swedish kronor (SEK)

Iconovo AB expands its collaboration with immunotherapy company Immune System Regulation (ISR) that accelerates the development of an inhaled vaccine for covid-19. The contract value of the collaboration between ISR and Iconovo increases by 13.6 million SEK. Iconovo is also entitled to low, single-digit royalty on the sale of the finalized product.

Abbreviated year-end report 1 January – 31 December 2021

Significant progress in Iconovo’s three strategic business areas

Iconovo announces completion of comparative clinical study of ICOres budesonide/formoterol and Symbicort Turbuhaler

Iconovo AB (publ), a company developing complete inhalation products for a global market, today announces that a clinical pilot pharmacokinetic study, comparing the pharmacokinetic profile of ICOres budesonide/formoterol and Symbicort® Turbuhaler®, has been successfully concluded. The study, which was carried out by Amneal Pharmaceuticals, has provided valuable data that supports continued development of ICOres budesonide/formoterol as a potential generic substitution of Symbicort® Turbuhaler® for the management of asthma and COPD.